Document is current
Any future updates will be listed below
-
Authors
Green, Alanna C. https://orcid.org/0000-0002-0175-1485
Marttila, Petra https://orcid.org/0000-0002-0115-8067
Kiweler, Nicole https://orcid.org/0000-0001-7493-703X
Chalkiadaki, Christina
Wiita, Elisée
Cookson, Victoria
Lesur, Antoine
Eiden, Kim
Bernardin, François https://orcid.org/0000-0002-6329-5542
Vallin, Karl S. A.
Borhade, Sanjay
Long, Maeve
Ghahe, Elahe Kamali
Jiménez-Alonso, Julio J.
Jemth, Ann-Sofie https://orcid.org/0000-0002-7550-1833
Loseva, Olga
Mortusewicz, Oliver https://orcid.org/0000-0002-4290-4994
Meyers, Marianne
Viry, Elodie
Johansson, Annika I. https://orcid.org/0000-0001-5000-1288
Hodek, Ondřej https://orcid.org/0000-0001-8307-9575
Homan, Evert
Bonagas, Nadilly https://orcid.org/0000-0001-7336-4065
Ramos, Louise https://orcid.org/0000-0002-3808-6853
Sandberg, Lars
Frödin, Morten
Moussay, Etienne https://orcid.org/0000-0002-0879-8067
Slipicevic, Ana
Letellier, Elisabeth https://orcid.org/0000-0001-8242-9393
Paggetti, Jérôme https://orcid.org/0000-0001-9460-5876
Sørensen, Claus Storgaard
Helleday, Thomas https://orcid.org/0000-0002-7384-092X
Henriksson, Martin https://orcid.org/0000-0002-2230-4887
Meiser, Johannes https://orcid.org/0000-0002-9093-6210
-
Funding
Funding for this research was provided by:
Weston Park Cancer Centre and the University of Sheffield
Helleday Foundation
Deutsche Forschungsgemeinschaft (KI 2508/1-1)
Fonds National de la Recherche Luxembourg (A18/BM/11809970, PRIDE19/14254520, 7.4509.20, 7.4572.22, C20/BM/14582635, C20/BM/14592342, A18/BM/11809970, C21/BM/15718879, PRIDE19/14254520)
Ministerio de Universidades of the Spanish Government
Karolinska Institute’s KID funding for doctoral students
One-Carbon Therapeutics AB
Novo Nordisk Fonden (17OC0029972)
Cancerfonden (2018/600, 2021/1490)
Barncancerfonden (2018-0095, 2021-0030)
Vetenskapsrådet (2015-00162, 2017-06095)
VINNOVA (2018-00257, 2021-04817)
Weston Park Cancer Centre and the University of Sheffield Torsten and Ragnar Söderberg Foundation
- License Information
-
More Information
Article History
Received: 12 August 2022
Accepted: 28 February 2023
First Online: 3 April 2023
Competing interests
: MTHFD1/2 inhibitors are developed toward the clinic by the company One-Carbon Therapeutics AB. A.S. is an employee of One-Carbon Therapeutics AB. T.H. owns shares in One-Carbon Therapeutics AB and P.M., E.W., S.B., A.-S.J., O.L., O.M., E.H., N.B. and M.H. have rights to One-Carbon Therapeutics AB. The remaining authors declare no competing interests.
